April 24 (Reuters) - Race Oncology Ltd RAC.AX :
* IND FOR BISANTRENE PHASE 2/3 CLINICAL TRIAL NOW ON CLINICAL HOLD WITH FDA, PENDING RESOLUTION OF OUTSTANDING FDA QUESTIONS
* RACE ONCOLOGY LTD ISSUES BISANTRENE IND (INVESTIGATIONAL NEW DRUG APPLICATION) UPDATE